Health & Fitness
Tue, May 1, 2012Mon, April 30, 2012Sun, April 29, 2012Sat, April 28, 2012Fri, April 27, 2012Thu, April 26, 2012Wed, April 25, 2012Tue, April 24, 2012Mon, April 23, 2012Sun, April 22, 2012Sat, April 21, 2012Fri, April 20, 2012Thu, April 19, 2012Wed, April 18, 2012MiMedx Group, Inc. Announces Release Date for 2012 First Quarter Results
Published in Health and Fitness on Tuesday, April 24th 2012 at 13:47 GMT by Market Wire
MiMedx Group, Inc. Announces Release Date for 2012 First Quarter Results -- KENNESAW, Ga., April 24, 2012 /PRNewswire/ --
MiMedx Group, Inc. Announces Release Date for 2012 First Quarter Results
KENNESAW, Ga., April 24, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2012, will be released before the opening of the market on Wednesday, May 2, 2012. MiMedx will host a live broadcast of its first quarter conference call on Wednesday May 2, 2012 at 10:30am Eastern Time. A listen-only simulcast of the MiMedx Group conference call will be available online at the Company's website at [ www.mimedx.com ] or at [ www.earnings.com ]. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast. The replay can also be found on the Company's website at [ www.mimedx.com ] or [ www.earnings.com ].
About the Company
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 70,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.
[ Back to top ] RELATED LINKS
[ http://www.mimedx.com ]
